Research news

UCLH has been selected as the lead site in Great Britain for Neuralink’s GB-PRIME study, a clinical investigation for Neuralink’s brain-computer interface (BCI).

UCLH has recruited the first participant in the UK to a study looking at a new investigational drug for patients with a condition affecting the blood vessels in the brain called cerebral amyloid angiopathy (CAA).

A clinical trial for patients newly diagnosed with glioblastoma, an aggressive form of brain cancer, has opened at the NIHR UCLH Clinical Research Facility based in the National Hospital for Neurology and Neurosurgery.

Initial results from an early phase study testing the safety and efficacy of a new drug for multiple myeloma have shown a 100 per cent overall response rate in patients with recurrent disease who were given the clinically recommended dose of the investigational drug.

Learn more about how UCLH celebrated Research Open Day this month.